You are here: vision-research.eu » News » Newsdetails:

FDA debates trial-data secrecy

Despite a trend towards increased transparency in clinical-trial data, the US Food and Drug Administration (FDA) is asking whether there are times when participants and researchers should be kept in the dark.

As pharmaceutical companies push for studies that first justify a drug’s approval, then monitor safety once it reaches the market, the agency fears that publicizing the early data could bias the final results.

General Research Business

Related Links